At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 143 enrolled
Drug / intervention
lesinuraddrug
Likely dose
lesinurad 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-Term Open-Label Extension Study for Subjects Completing a Phase 3 Efficacy and Safety Study of Lesinurad Monotherapy in Subjects With Gout
In Brief
A Phase 3 clinical trial evaluating lesinurad for Gout. Completed, enrolled 143 participants across 75 sites in 7 countries.
Detailed Summary
This study will assess the serum uric acid lowering effects and safety of lesinurad over a long-term timeframe.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGout
CountriesAustralia, Belgium, Canada, Germany, New Zealand, South Africa, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartAug 2012
Primary CompletionApr 2014
Study CompletionAug 2014
TodayJul 2026
First PostedJul 26, 2012
Enrollment StartAug 1, 2012
Primary CompletionApr 1, 2014
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.9 years ago
Interventions
lesinuraddrug
Tablets, 400 mg QD